The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus
Cipla announced the launch of Afrezza (insulin human) Inhalation Powder in India. Cipla had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) late last year, for the exclusive distribution and marketing of Afrezza, a rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy. The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus.
The insulin inhalation powder in Afrezza is available in single use cartridges and is delivered via an inhaler device. The process of inhaling insulin is simple — selecting the appropriate dose cartridge, loading the cartridge in the inhaler device, inhaling the insulin from the device and removing the cartridge from the device. Afrezza, which is created and manufactured by MannKind Corporation (MannKind) USA, dissolves rapidly upon oral inhalation and begins lowering blood glucose within approximately 12 minutes, closely mirroring the body’s natural insulin response. By offering a needle-free, rapid-acting alternative to daily prandial injections, it is designed to support better adherence and enable quicker glycemic control for adults with both type 1 and type 2 diabetes mellitus.
Achin Gupta, Global Chief Operating Officer, Cipla, said, “At Cipla, our purpose has always been simple – to make quality healthcare more accessible for every patient. The introduction of Afrezza in India reflects that responsibility. This innovation not only simplifies insulin delivery but also eases many of the emotional and practical barriers patients face with daily insulin injections. With our reach and our deep commitment to patient well-being, we hope to support millions of Indians in managing their diabetes with greater confidence and comfort.”
